文献速递炎症性肠病

环丙沙星与甲硝唑治疗初发储袋炎的疗效比较:一项倾向匹配研究

The Comparative Effectiveness of Ciprofloxacin and Metronidazole for an Initial Episode of Pouchitis: A Propensity-Matched Study.
PubMed 文献 · Am J Gastroenterol · 2023-07-19

该回顾性队列研究基于TriNetX数据库,纳入271例溃疡性结肠炎行回肠储袋肛管吻合术后发生储袋炎的患者,比较环丙沙星单药、甲硝唑单药及联合治疗初发储袋炎的疗效。倾向匹配后,环丙沙星与甲硝唑单药相比,早期复发或无效的调整OR为0.56(95%CI 0.23-1.34),复发储袋炎的调整OR为0.86(95%CI 0.40-1.84);任一单药与联合治疗相比亦无显著差异。结论认为三种方案在真实世界中的疗效无显著差异。

要点

  • 倾向匹配后,环丙沙星与甲硝唑单药治疗初发储袋炎的早期复发或无效风险无显著差异(调整OR 0.56,95%CI 0.23-1.34)。
  • 两单药分别与联合治疗相比,早期复发或无效以及复发储袋炎的 odds 均无显著差异。
  • 271例患者中190例(70%)在初发储袋炎后12个月内出现复发性储袋炎。

核心结论

  • 在这项回顾性队列研究中,环丙沙星、甲硝唑或联合治疗初发储袋炎的真实世界疗效无显著差异。

研究设计与样本

  • 回顾性队列研究,使用全球联邦电子健康记录研究网络TriNetX。
  • 纳入271例溃疡性结肠炎行回肠储袋肛管吻合术后发生储袋炎并接受环丙沙星、甲硝唑或联合治疗的患者(回肠储袋肛管吻合时平均年龄35.8岁,男性57%)。
  • 对年龄、性别、种族、原发性硬化性胆管炎、尼古丁依赖、肥胖及既往肿瘤坏死因子抑制剂暴露进行一对一倾向评分匹配。

主要发现

  • 271例患者中190例(70%)发生复发性储袋炎。
  • 倾向匹配后,环丙沙星与甲硝唑单药相比,早期复发或无效的调整OR为0.56(95%CI 0.23-1.34),无显著差异。
  • 倾向匹配后,环丙沙星与甲硝唑单药相比,复发性储袋炎的调整OR为0.86(95%CI 0.40-1.84),无显著差异。
  • 任一单药与联合治疗相比,早期复发或无效及复发性储袋炎的 odds 均无显著差异。

关键数值与推荐

  • 主要结局为初始抗生素治疗失败及初发储袋炎后12个月内发生复发性储袋炎。
  • 环丙沙星 vs 甲硝唑单药:早期复发或无效调整OR 0.56(95%CI 0.23-1.34)。
  • 环丙沙星 vs 甲硝唑单药:复发性储袋炎调整OR 0.86(95%CI 0.40-1.84)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There is minimal evidence regarding the comparative effectiveness of individual antibiotics in the treatment of pouchitis. We sought to evaluate the comparative effectiveness of ciprofloxacin monotherapy, metronidazole monotherapy, and combination therapy (ciprofloxacin and metronidazole) in the treatment of an initial episode of pouchitis after ileal pouch-anal anastomosis for ulcerative colitis (UC). METHODS: We performed a retrospective cohort study in TriNetX, a global federated research network of electronic health records. Primary outcomes were failure of initial antibiotic therapy and the development of recurrent pouchitis in the first 12 months after an initial episode of pouchitis. One-to-one propensity score matching was performed for age, sex, race, primary sclerosing cholangitis, nicotine dependence, obesity, and previous exposure to tumor necrosis factor inhibitors between the cohorts. RESULTS: Among 271 patients who developed pouchitis (mean age at ileal pouch-anal anastomosis 35.8 years, male sex 57%) and were treated with ciprofloxacin, metronidazole, or combination therapy, 190 (70%) developed recurrent pouchitis. After propensity score matching, there was no significant difference in the odds of early relapse or nonresponse with ciprofloxacin compared with metronidazole monotherapy (adjusted odds ratio 0.56, 95% confidence interval 0.23-1.34) or when either monotherapy was compared with combination therapy. There was also no significant difference in odds of recurrent pouchitis when comparing patients treated with ciprofloxacin with metronidazole monotherapy (adjusted odds ratio 0.86, 95% confidence interval 0.40-1.84) or either monotherapy with combination therapy. DISCUSSION: In this retrospective cohort study, we demonstrated no significant difference in the real-world effectiveness of ciprofloxacin, metronidazole, or combination therapy for the initial episode of pouchitis.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Barnes EL, Desai A, Kochhar GS, et al. The Comparative Effectiveness of Ciprofloxacin and Metronidazole for an Initial Episode of Pouchitis: A Propensity-Matched Study. Am J Gastroenterol. 2023. PMID: 37463438. doi:10.14309/ajg.0000000000002412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。